Zejing Pharmaceutical announced that a randomized controlled key clinical trial of ZG006 monotherapy with a class 1 new drug independently developed by the company to treat patients with advanced small cell lung cancer that had recurred or progressed after platinum-containing chemotherapy and at least 1 other system treatment completed the pre-set mid-term analysis, and the independent data monitoring committee determined that the main target was reached after review. The study was conducted in more than 50 hospitals. 115 subjects were randomly treated 2:1 with ZG006 10mg Q2W and the treatment selected by the researchers. The company will submit a pre-BLA communication application to the CDE to accelerate the listing process.

Zhitongcaijing · 2d ago
Zejing Pharmaceutical announced that a randomized controlled key clinical trial of ZG006 monotherapy with a class 1 new drug independently developed by the company to treat patients with advanced small cell lung cancer that had recurred or progressed after platinum-containing chemotherapy and at least 1 other system treatment completed the pre-set mid-term analysis. The independent data monitoring committee determined that the main target was reached after review. The study was conducted in more than 50 hospitals. 115 subjects were randomly treated 2:1 with ZG006 10mg Q2W and the treatment selected by the researchers. The company will submit a pre-BLA communication application to the CDE to accelerate the listing process.